html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

Aims

We aim to center our research around the following three topics:

Preclinical cancer pharmacology
Clinical cancer pharmacology
Dose individualization

go to main content

Go to Radboudumc Radboudumc

Research group Cancer pharmacology

Welcome to Research

type a search term here ...

information on how Radboudumc conducts research →
opportunities for my career within Radboudumc research →
opportunities to participate or invest in Radboudumc research →

Research Research groups Cancer pharmacology

About Cancer pharmacology

We focus on describing, explaining, understanding and modifying the pharmacokinetics of oral anticancer drugs.

Research group leader

prof. dr. Nielka van Erp

Aims

See our most important goals.

read more

Publications

See some of our most important scientific articles.

read more

Publications

See the publication list of the research group leader on Web of Science.

Profile page

See the group leader's profile.

see page

Research programs

Programs that are connected to this research group.